Unfortunately, first measurements in human SCA2 patient serum samples revealed that the level of expanded ATXN2 is lower as the determined immunoassay LOQ and therefore not high enough for evaluation with the newly developed TR-FRET-based immunoassay. This evidence concerns the gene ATXN2 and spinocerebellar ataxia type 2.